EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Integrating novel agents into the treatment of advanced mycosis fungoides and Sézary syndrome

Michael S Khodadoust iD, Eric Mou iD, Youn H Kim iD

Blood · 16.02.2023 · 141 (7) · 695-703

DOI: 10.1182/blood.2020008241 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Blood, erschienen am 16.02.2023. Verfasst von Michael S Khodadoust und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Oncology, Stanford University, Stanford, CA. Hauptthemen laut MEDLINE: Sezary Syndrome, Skin Neoplasms, Mycosis Fungoides. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Agents targeting the unique biology of mycosis fungoides and Sézary syndrome are quickly being incorporated into clinical management. With these new therapies, we are now capable of inducing more durable responses and even complete remissions in advanced disease, outcomes which were exceedingly rare with prior therapies. Yet, even this new generation of therapies typically produce objective responses in only a minority of patients. As our therapeutic options increase, we are now challenged with selecting treatments from a growing list of options. To gain the full benefit of these novel agents, we must develop strategies to match treatments for the patients most likely to benefit from them. Here, we consider both the current approaches to treatment selection based on clinical features and the future of molecular biomarker-guided therapy for patients with this heterogeneous disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sezary SyndromeSkin NeoplasmsMycosis FungoidesHumans

Autor:innen und Institutionen

  • Division of Oncology, Stanford University, Stanford, CA.
  • Department of Dermatology, Stanford University, Stanford, CA.
  • Division of Hematology, Oncology, and Blood & Marrow Transplantation, University of Iowa, Iowa City, IA.

ORCID-Profile: Michael S Khodadoust, Eric Mou, Youn H Kim

Zitieren

APA

Khodadoust, M. S., Mou, E., & Kim, Y. H. (2023). Integrating novel agents into the treatment of advanced mycosis fungoides and Sézary syndrome. Blood, 141(7), 695-703. https://doi.org/10.1182/blood.2020008241

Vancouver

Khodadoust MS, Mou E, Kim YH. Integrating novel agents into the treatment of advanced mycosis fungoides and Sézary syndrome. Blood. 2023;141(7):695-703. doi:10.1182/blood.2020008241

BibTeX
@article{Khodadoust2023,
  author = {Khodadoust, Michael S and Mou, Eric and Kim, Youn H},
  title = {Integrating novel agents into the treatment of advanced mycosis fungoides and Sézary syndrome},
  journal = {Blood},
  year = {2023},
  volume = {141},
  number = {7},
  pages = {695--703},
  doi = {10.1182/blood.2020008241}
}
Kostenlos starten →